Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 26;33(34):e213.
doi: 10.3346/jkms.2018.33.e213. eCollection 2018 Aug 20.

Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records

Hun-Sung Kim  1   2 , Suehyun Lee  3 , Ju Han Kim  3
Affiliations

Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records

Hun-Sung Kim et al. J Korean Med Sci. .

Abstract

Real-world evidence (RWE) and randomized control trial (RCT) data are considered mutually complementary. However, compared with RCT, the outcomes of RWE continue to be assigned lower credibility. It must be emphasized that RWE research is a real-world practice that does not need to be executed as RCT research for it to be reliable. The advantages and disadvantages of RWE must be discerned clearly, and then the proper protocol can be planned from the beginning of the research to secure as many samples as possible. Attention must be paid to privacy protection. Moreover, bias can be reduced meaningfully by reducing the number of dropouts through detailed and meticulous data quality management. RCT research, characterized as having the highest reliability, and RWE research, which reflects the actual clinical aspects, can have a mutually supplementary relationship. Indeed, once this is proven, the two could comprise the most powerful evidence-based research method in medicine.

Keywords: Randomized Control Trial; Real-world Data; Real-world Evidence.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no potential conflicts of interest to disclose.

References

    1. Garrison LP, Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10(5):326–335. - PubMed
    1. Kim HS, Lee H, Lee SH, Jeong YJ, Kim TM, Yang SJ, et al. Use of moderate-intensity statins for low-density lipoprotein cholesterol level above 190 mg/dL at baseline in Koreans. Basic Clin Pharmacol Toxicol. 2017;121(4):272–278. - PubMed
    1. Kim HS, Lee H, Park B, Park S, Kim H, Lee SH, et al. Comparative analysis of the efficacy of low- and moderate-intensity statins in Korea. Int J Clin Pharmacol Ther. 2016;54(11):864–871. - PubMed
    1. Jeong YJ, Kim H, Baik SJ, Kim TM, Yang SJ, Lee SH, et al. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea. J Clin Pharm Ther. 2017;42(3):292–300. - PubMed
    1. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES) Int J Epidemiol. 2014;43(1):69–77. - PMC - PubMed